Introduction
============

Upper tract urothelial carcinoma (UTUC), accounting for only 5% of all urothelial cancers, is a rare malignancy with high risk for disease recurrence and mortality ([@ref-22], [@ref-22]). Given its high potential for recurrence and poor prognosis, assessment of the predictive factors appears to be increasingly significant. Tumor multifocality, previous bladder cancer and concomitant carcinoma *in situ* (CIS) have been validated as predictors of intravesical recurrence, which is also associated with different surgical approaches ([@ref-29]; [@ref-30]). The standard treatment for UTUC is nephroureterectomy with bladder cuff excision. The treatment approaches include open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU). Compared with ONU, a traditional approach which has durable oncologic control, LNU has shown several advantages with fewer adverse intra- and perioperative outcomes as a minimally invasive treatment since being first introduced by Clayman in 1991 ([@ref-3], [@ref-3]; [@ref-24], [@ref-24]). However, compared to ONU, whether LNU has equivalent oncological outcomes, such as cancer-specific survival (CSS) and intravesical recurrence-free survival (IRFS), remains controversial ([@ref-10], [@ref-10]; [@ref-30], [@ref-30]). We aimed to perform a meta-analysis to evaluate the oncological control associated with different surgical approaches (ONU vs LNU).

Methods
=======

Search and screen strategy
--------------------------

A systematic literature search of Embase, PubMed, ISI Web of Knowledge and Cochrane Library was conducted to retrieve UTUC studies comprising both surgical approaches (ONU and LNU) through November 1, 2015. The search key words included *open nephroureterectomy*, *laparoscopic nephroureterectomy*, *upper tract urothelial carcinoma*, and others. The detailed search strategy is presented in [Supplemental Information 2](#supp-5){ref-type="supplementary-material"}. We also screened the citations in the retrieved articles for any relevant studies. Two independent investigators (S Zhang and Y Luo) conducted the initial screening by reviewing the title and abstract. Then, the full-text articles satisfying the inclusion criteria were reviewed. Clinical studies recording any evaluation of the surgical approach on oncological outcomes, including intravesical recurrence-free survival (IRFS), extravesical recurrence-free survival (ExRFS), unspecified recurrence-free survival (UnRFS, reported as disease recurrence but not explicitly defined as IRFS or ExRFS), cancer-specific survival (CSS) or overall survival (OS), were eligible. Articles were excluded if they met any of the following criteria: (1) the aforementioned outcomes were not described; (2) patients were treated by hand assisted laparoscopic nephroureterectomy; or (3) studies included overlapping patients or duplicated data. Instead, the study with the largest sample size would be selected if more than one study included overlapping patients. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) ([@ref-17], [@ref-17]). Ethical approval and patient consent were waived because all available data were extracted from previous publications.

Data extraction and assessment of methodological quality
--------------------------------------------------------

The basic information including first author, year of publication, region, recruitment period, number of patients who underwent LNU or ONU, age of patients, follow-up, oncological outcomes, and adjusted factors were extracted by two researchers (S Zhang and Y Luo) independently. Any disagreement or uncertainty was determined by group discussion, and a consensus was obtained. The data were extracted from the original articles. For incomplete data, we attempted to contact the corresponding author to acquire primary data. During data extraction, multivariate outcomes rather than univariate outcomes were preferred when both results were provided. If multivariate results were not available, univariate outcomes were an alternative to conduct this analysis. Publication bias and sensitivity analyses were applied. The quality assessments of cohort studies were conducted according to the Newcastle-Ottawa Scale (NOS), which was developed to assess bias risk including three domains with eight items. Five or more stars out of a total of nine stars was regarded as good quality ([@ref-28]).

Statistical analysis
--------------------

All data and analysis were conducted using STATA 13 software (Stata Corp LP, College Station, TX, USA). The survival outcomes were evaluated by hazard ratios (HR) and 95% confident intervals. *I*^2^ statistics and the chi-square test were calculated for heterogeneity detection. When *P* ≥ 0.1 and *I*^2^ ≤ 50%, a fixed-effects model was performed; otherwise, a random effects model was applied. An inverse variance method was used to calculate the pooled hazard ratio. Sensitivity analyses were conducted to test the stability of the pooled results. Egger's test for publication bias was performed only in outcomes that enrolled more than ten studies ([@ref-4], [@ref-4]). Additionally, we conducted subgroup and multivariable meta-regression in IRFS according to the different approach of LNU (retroperitoneal vs. transperitoneal), sample size of LNU (\<100 vs ≥100) and publication year. A *P* value of less than 0.05 was deemed statistically significant.

Results
=======

Description of included studies
-------------------------------

In total, 1,506 citations were retrieved by the initial search strategy. After three rounds of screening, there were 21 cohort studies for quantitative synthesis. The PRISMA flow diagram is presented in [Fig. 1](#fig-1){ref-type="fig"}. [Table 1](#table-1){ref-type="table"} shows the detailed characteristics of the included studies. The Newcastle Ottawa Scale (NOS) assessment showed that all included cohort studies had relatively well controlled quality.
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###### Characteristics of the studies included in the systematic review.
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  Study       Country         Duration           N of pts (ONU/LNU)   Age (yrs) (ORNU/LRNU)                Follow up (month) (ONU/ LNU)      Outcomes         Approach of LNU   NOS   Adjusted factors
  ----------- --------------- ------------------ -------------------- ------------------------------------ --------------------------------- ---------------- ----------------- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------
  [@ref-6]    USA             2002--2008         109/53               Md73 (IQR67-78) Md71 (IQR64-76)      Md23                              UnRFS, IRFS      Mixed             6     Age, ASA, pT, Grade, pN, CIS, PBC
  [@ref-7]    Canada          1990.1--2010.6     267/345              Md67 (IQR59-75)                      Md24.8 (IQR7.69-56.76)            IRFS             NA                7     Age, Smoking, PH, Previous abdominal radiotherapy, DUM, CIS, TL, AC
  [@ref-9]    Japan           2005.12--2008.11   39/33                NA                                   R2.6-39.3                         IRFS             RE                6     Sex, Age, TS, pT, UC, Grade, CIS, Histology type, AC
  [@ref-10]   Korea           1992--2012         271/100              Md64.7 (IQR57.7-70.8)                Md50.8 (IQR26.6-103.6)            OS, CSS, IRFS    TR                8     Age, ASA, PBC, UC, pT,Grade, LVI, Variant histology of urothelial carcinoma, TL, SM, AC
  [@ref-11]   Japan           1995.4--2010.8     34/65                Md69 (R32-88) Md65 (R53-71)          Md70 (R6-192)                     IRFS             Mixed             6     Grade
  [@ref-32]   CHN             1999.1--2013.2     101/21               Mn63.7 (R35-80)                      Md53 (R3-159)                     IRFS, CSS        TR                7     Gender, PH, TS, TL, Size, Appearance, Necrosis, pT, Grade, Multifocality, CIS, SM, LVI
  [@ref-31]   Canada          1990-/             591/46               Md68 (IQR61-75)                      Md37 (IQR18-68)                   ExRFS,CSS        NA                6     Age, Race, Gender, TL, pT, Grade, CIS, LVI, pN
  [@ref-27]   Multi central   1987--2008         703/70               Md68 (IQR61-75)                      Md34 (IQR15-65)                   ExRFS, CSS       NA                7     Age, Gender, Race, PBC, DUM, TL, Grade, pT, pN, LVI, CIS
  [@ref-25]   Thailand        2001.4--2007.1     29/31                Mn66.8 (R39-88) Mn63.8 (R26-79)      Mn27.9 (R3-63) Mn26.4 (R3-72)     UnRFS            RE                5     pT, Grade
  [@ref-15]   Canada          1990--2010         403/446              Mn69.7 (SD10.7)                      Mn26.4 (R7.2-60)                  UnRFS, OS        NA                8     Region, Age, Symptoms, TL, pT, Grade, CIS, PBC, NeoAC, AC, Salvage chemotherapy, Salvage radiation therapy, SM, Smoking, Previous abdominal RT, pN
  [@ref-14]   Japan           1996--2003         28/13                Mn65.07 (SD9.46) Mn65.31 (SD10.69)   Mn55.7 (SD29.4) Mn34.2 (SD10.9)   IRFS             RE                6     Multiple tumors, pT, Grade, OT
  [@ref-13]   Japan           1995.1--2005.8     27/29                Mn67.4 (SD11.3) Mn71.4 (SD8.2)       Mn46.2 (R1-97) Mn16.4 (R1-57.5)   IRFS             RE                6     Sex, Side, Age, pT, Grade, OT, AC, PBC
  [@ref-19]   Multicentres    1989--2012         2826/922             Md70 (IQR60-74)                      Md32.7 (IQR13.6-67.4)             IRFS, CSS        NA                7     Age, Sex, Ureter location, Multifocality, LN, DUM, pT, High grade, CIS, AC
  [@ref-21]   Muticentres     1987--2007         2042/450             Md69.2 (IQR62-77)                    Md36                              ExRFS, OS, CSS   NA                5     Univariable Cox regression
  [@ref-5]    Canada          1994--2009         403/446              Md70.5 Md72.4                        Md26.4 (IQR7.2-60)                UnRFS, OS, CSS   Mixed             7     Age, Sex, AC, pT, pN, Grade, SM
  [@ref-2]    Muticentres     1987-2007          979/270              Mn68.3 (R27-97) Mn70.2 (R36-94)      Md49                              ExRFS, CSS       NA                7     Age, pT, pN, Grade, LVI, ECOG PS, pN, PBC, Previous endoscopy, CIS
  [@ref-1]    France          1995--2010         459/150              Md69.8 (R60.9-76) Md69.5 (R63-77)    Md27 (R10-48)                     UnRFS, CSS,      TR                6     Gender, Age, ASA physical status, TL, pT, Grade, pN, LVI
  [@ref-12]   Japan           2005.1--2009.4     151/137              Md71.4 (R32-89)                      Md20.2 (R3.0-61.6)                IRFS             RE                6     TL, Time of ligation of the ureter, UC.
  [@ref-26]   Japan           2000.1--2005.12    111/66               Mn71.3 (SD9.6) Mn 68.7 (SD9.5)       Mn31 (R12.0-80.5)                 IRFS             RE                7     Age, TS, TL, Multifocality, OT, DUM, pT, Grade, pN, LVI, SM
  [@ref-8]    Japan           1990--2005         165/43               Md70 (R39-90)                        Md8 (R2-105)                      IRFS, CSS        RE                5     Univariable Cox regression
  [@ref-29]   France          1995--2009         350/132              Mn69.2 (IQR60-76)                    Mn39.5 (IQR25-60)                 IRFS             NA                6     Age, Gender, TL, Multifocality, PBC, Endoscopic management, pT, Grade, CIS, LVI, pN

**Notes.**

List of abbreviationsyrsyearsN of ptsnumber of patientsMnmeanMdmedianRrangeIQRinterquartile rangeNAnot applicableIRFSintravesical recurrence free survivalExRFSextravesical recurrence free survivalUnRFSunspecified recurrence free survivalOSoverall survivalCSScancer specific survivalREretroperitonealTRtransperitonealNOSNewcastle-Ottawa ScalepTpTstagepNpNstageTLtumor locationPHprevious hydronephrosisDUMdistal ureter managementTStumor sideUCurinary cytologySMsurgical marginPBCprevious bladder cancerASAAmerican Society of Anesthesiology physical statusACadjuvant chemotherapyOToperation timeCIScarcinoma *in situ*LVIlymphovascular invasionECOG PSEastern Cooperative Oncology Group performance score

Survival outcomes
-----------------

### Oncological recurrence

The IRFS was reported in thirteen articles, which included LNU (*n* = 1,959) and ONU (*n* = 4,281) ([@ref-6], [@ref-6]; [@ref-7], [@ref-7]; [@ref-8], [@ref-8]; [@ref-9], [@ref-9]; [@ref-10], [@ref-10]; [@ref-11], [@ref-11]; [@ref-12], [@ref-12]; [@ref-13], [@ref-13]; [@ref-14], [@ref-14]; [@ref-19], [@ref-19]; [@ref-26], [@ref-26]; [@ref-29], [@ref-29]; [@ref-32], [@ref-32]). The meta-analysis results showed no significant difference in the IRFS between LNU and ONU management (HR 1.05, 95% CI \[0.92--1.18\]; *P* = 0.134, *I*^2^ = 31.1%; [Fig. 2](#fig-2){ref-type="fig"}). The ExRFS was described in four studies including patients who underwent LNU (*n* = 836) and ONU (*n* = 4,315) ([@ref-2], [@ref-2]; [@ref-21], [@ref-21]; [@ref-27], [@ref-27]; [@ref-31], [@ref-31]). The pooled results showed that LNU management decreased the risk of extravesical recurrence (HR 0.80, 95% CI \[0.64--0.96\]; *P* = 0.859, *I*^2^ = 0.0%; [Fig. 3](#fig-3){ref-type="fig"}). Five studies including LNU (*n* = 1,126) and ONU (*n* = 1,403) ([@ref-1], [@ref-1]; [@ref-5], [@ref-5]; [@ref-6], [@ref-6]; [@ref-15], [@ref-15]; [@ref-25], [@ref-25]) reported the UnRFS. The pooled analysis of the available HRs showed that the different surgical procedures were not significantly correlated with disease recurrence (HR 1.10, 95% CI \[0.93--1.28\]; *P* = 0.337, *I*^2^ = 12.0%; [Fig. 4](#fig-4){ref-type="fig"}).

![Forest plot of Intravesical Recurrence Free Survival (IRFS) hazard ratio.](peerj-04-2063-g002){#fig-2}

![Forest plot of Extravesical Recurrence Free Survival (ExRFS) hazard ratio.](peerj-04-2063-g003){#fig-3}

![Forest plot of Unspecified Recurrence Free Survival (UnRFS) hazard ratio.](peerj-04-2063-g004){#fig-4}

### Mortality

Among the four studies that provided the HRs of OS, there were 1,442 LNU patients and 3,119 ONU patients ([@ref-5], [@ref-5]; [@ref-10], [@ref-10]; [@ref-15], [@ref-15]; [@ref-21], [@ref-21]). There was significant heterogeneity (*P* = 0.091, *I*^2^ = 53.7%; [Fig. 5](#fig-5){ref-type="fig"}), and a random model was applied. The model showed that neither LNU nor ONU significantly increased the risk in the overall survival (HR 0.91, 95% CI \[0.66--1.17\]; [Fig. 5](#fig-5){ref-type="fig"}). The CSS was described in ten articles, in which 2,518 patients were treated by LNU and 8,342 patients were treated by ONU ([@ref-1], [@ref-1]; [@ref-2], [@ref-2]; [@ref-5], [@ref-5]; [@ref-8], [@ref-8]; [@ref-10], [@ref-10]; [@ref-19], [@ref-19]; [@ref-21], [@ref-21]; [@ref-27], [@ref-27]; [@ref-31], [@ref-31]; [@ref-32], [@ref-32]). The pooled results indicated that LNU could improve the cancer specific survival (HR 0.79, 95% CI \[0.68--0.91\]; *P* = 0.186, *I*^2^ = 28.1%; [Fig. 6](#fig-6){ref-type="fig"}).

![Forest plot of Overall Survival (OS) hazard ratio.](peerj-04-2063-g005){#fig-5}

![Forest plot of Cancer Specific Survival (CSS) hazard ratio.](peerj-04-2063-g006){#fig-6}

### Subgroup analysis and multivariable meta-regression for IRFS

In subgroup analysis for the effect of different approaches of LNU on IRFS, no difference were seen among people with retroperitoneal laparoscopy (HR 1.04, 95% CI \[0.77--1.32\]; *P* = 0.598, *I*^2^ = 0.0%; [Fig. 7](#fig-7){ref-type="fig"}) and transperitoneal laparoscopy (HR 0.81, 95% CI \[0.48--1.13\]; *P* = 0.548, *I*^2^ = 0.0%; [Fig. 7](#fig-7){ref-type="fig"}). The subgroup of five studies with sample sizes of LNU more than 100 had a combined HR of 1.31 (95% CI\[0.92--1.70\]) with significant heterogeneity (*P* = 0.011, *I*^2^ = 69.5%; [Fig. 8](#fig-8){ref-type="fig"}), while the subgroup of eight studies with sample sizes of less than 100 had a combined HR of 0.97 (95% CI \[0.67--1.16\]) without significant heterogeneity (*P* = 0.919, *I*^2^ = 0.0%; [Fig. 8](#fig-8){ref-type="fig"}). Multivariable meta-regression showed no particular influence of different approaches of LNU (*P* = 0.431), sample size (*P* = 0.899) and publication year (*P* = 0.729) on the results.

![Forest plot of subgroup analysis for IRFS - stratified by LNU approach.](peerj-04-2063-g007){#fig-7}

![Forest plot of subgroup analysis for IRFS---stratified by sample size.](peerj-04-2063-g008){#fig-8}

Publication bias and sensitivity analysis
-----------------------------------------

The publication bias detection was conducted by Egger's asymmetric test and only for IRFS outcomes. The *P* value of the linear regression was 0.515, and no significant publication bias was observed ([Fig. S1](#supp-1){ref-type="supplementary-material"}). We also performed sensitivity analyses of IRFS and CSS, and no significance change was observed ([Figs. S2](#supp-2){ref-type="supplementary-material"} and [S3](#supp-3){ref-type="supplementary-material"}).

Discussion
==========

Recently, some retrospective studies have paid attention to the predictors of disease recurrence in patients with UTUC after RNU; these studies found that CIS, previous bladder cancer, laparoscopic surgery and distal ureteral management were risk factors for disease recurrence ([@ref-30], [@ref-30]). A systemic review concluded that a laparoscopic approach significantly increased the risk of intravesical recurrence ([@ref-23], [@ref-23]). However, there are many studies that suggested that laparoscopic surgery could provide equivalent oncologic control compared with open surgery ([@ref-6], [@ref-6]; [@ref-8], [@ref-8]). Therefore, we conducted this meta-analysis enrolling twenty-one retrospective studies that contained various oncologic outcomes to assess whether LNU would show a tendency toward a poor prognosis for UTUC patients.

Open nephroureterectomy, the traditional surgical approach that could support a durable tumor control, has long been accepted as the standard surgical treatment for UTUC, especially for high-risk UTUC ([@ref-22], [@ref-22]). As a viable minimally invasive therapy, LNU was developed in an effort to reduce the morbidity of the surgical management and had advantages of lesser blood loss, shorter hospital stay and oncologic outcomes compared with ONU. With a median follow-up of 45 months of 1,261 UTUC patients who underwent ONU (*n* = 926) or LNU (*n* = 335), [@ref-30] showed that the laparoscopic approach was associated with a higher risk of intravesical recurrence compared with open surgery (HR = 1.5, 95% CI \[1.17--1.93\]). It was suggested that the high pressure pneumoperitoneum during LNU might trigger tumor dissemination and could result in a higher rate of recurrence, which contributed to the debate on oncologic outcomes of UTUC patients after laparoscopic procedures. Few cases of laparoscopic port-side seeding were reported in some literature in the early years, and [@ref-22] proposed that ensuring a closed system during laparoscopic surgery and avoiding direct contact between instruments and tumors might favor tumor control. In 150 laparoscopic surgeries, ([@ref-1], [@ref-1]) reported three cases of laparoscopic port-side seeding occurred in early experiences. After the widespread use of laparoscopic bags for specimen extraction, no cases happened. Our pooled results demonstrated that LNU could provide equivalent tumor control of intravesical recurrence and unspecified RFS compared to ONU. However, the majority of the enrolled studies reported negative control for ONU in extravesical recurrence. Our results showed that ONU was an independent risk for ExRFS. However, considering that there were only four articles enrolled, whether open surgery increased the risk of extravesical recurrence still needs further exploration. Our analysis based on the current evidence did not support the view that laparoscopic surgery increased the risk of disease recurrence of patients with UTUC after nephroureterectomy.

Regarding survival outcomes, our data demonstrated that LNU was comparable to ONU in overall survival, and superior in cancer specific survival. In the first randomized prospective study, the cancer specific survival rate and the metastasis free survival rate were significantly different between the LNU and ONU groups, which favored ONU after matching for pT3 and high-grade tumors ([@ref-24], [@ref-24]). In the 2015 EAU guidelines, invasive or large (T3/T4 and/or N+/M+) tumors were deemed as contraindications for a laparoscopic approach ([@ref-22], [@ref-22]). Recently, [@ref-10] ([@ref-10]) retrospectively analyzed the data of 371 UTUC patients who underwent ONU (*n* = 271) or LNU (*n* = 100); the results indicated that LNU had worse five-year OS and CSS rates than the ONU group only in locally advanced disease (pT3/T4) after stratifying by pathological stages. However, this conclusion was not identified in Arian's research in tumors of the pathological stages of pT3/T4 ([@ref-1], [@ref-1]). A recent study including 749 muscle-invasive UTUC patients who underwent ONU (*n* = 527) or LNU (*n* = 222) also indicated that the oncological outcomes of LNU were not inferior to the outcomes of ONU ([@ref-16], [@ref-16]). Although our analysis did not include a subgroup analysis of survival outcomes (OS and CSS) in locally advanced UTUC patients because of a lack more relevant survival data, our results might be reliable because the majority of our data were extracted from multivariate analyses, the majority of which adjusted for the effect of tumor stages and grades. Furthermore, a previous systematic review also showed that no significant differences in the stages of pT3/T4 or pathologic grades were observed in the LNU group compared with the ONU group ([@ref-18], [@ref-18]).

Previous systematic reviews on the oncologic outcomes comparing LNU with ONU were published in 2012 ([@ref-18], [@ref-18]; [@ref-20], [@ref-20]). These cumulative analyses conducted by using non-time to event data suggested that LNU could offer reliable perioperative safety and comparable oncologic efficacy compared to ONU. The meta-analysis conducted by Ni et al. indicated that LNU could improve the 5-yr CSS and decrease the rates of the overall recurrence and bladder recurrence. Recently, [@ref-23] ([@ref-23]) observed that LNU was a significant predictor of the IRFS in their meta-analysis enrolling in six studies (HR 1.62; 95% CI \[1.18--2.22\]). After enrolling more available HRs extracted from multivariate or univariable Cox regression, our results showed there was no significant difference in IRFS between LNU and ONU management, different from the studies of Ni et al. and Seisenet al. We thought the conclusion that LNU could improve the CSS should be interpreted cautiously, although this conclusion was consistent with the previous opinion of Ni et al.

Several limitations must be acknowledged in our meta-analysis. First, this meta-analysis was based on retrospective studies. Although all of these studies were of high quality (\>5 stars) according to the modified Newcastle-Ottawa Scale, the intrinsic bias of cohort studies existed. Next, the covariates controlled in the Cox regression analysis were different, which might introduce bias into our analysis. Finally, the time interval of the studies enrolled was more than 20 years. During this period, improvements in surgical techniques and medical materials should be considered. Additionally, these analyses did not include hand assisted laparoscopic nephroureterectomy because its relevant HR by Cox regression analysis for oncologic outcomes was reported in few literatures, and it is frequently deemed as an inferior approach compared with LNU or ONU in terms of the recurrence free survival and intravesical recurrence free survival rates ([@ref-11], [@ref-11]). Given the low incidence of UTUC, high-quality level data were so scarce that our results should be interpreted cautiously. The oncological outcomes of LNU and ONU should be verified by prospective randomized controlled trials, especially for locally advanced disease.

Conclusion
==========

Based on our meta-analysis of the current evidence, LNU could provide equivalent prognostic effects for upper tract urothelial carcinoma as ONU, and LNU had better results in the ExRFS and CSS. However, considering all eligible studies with the intrinsic bias of retrospective study design, the results should be interpreted with caution, and prospective randomized controlled trials are still needed.
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